195 related articles for article (PubMed ID: 9680056)
1. Pharmacotherapy of attention-deficit/hyperactivity disorder in adults.
Wender PH
J Clin Psychiatry; 1998; 59 Suppl 7():76-9. PubMed ID: 9680056
[TBL] [Abstract][Full Text] [Related]
2. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo.
Levin FR; Evans SM; Brooks DJ; Kalbag AS; Garawi F; Nunes EV
Drug Alcohol Depend; 2006 Feb; 81(2):137-48. PubMed ID: 16102908
[TBL] [Abstract][Full Text] [Related]
3. Stimulant treatment of adult attention-deficit/hyperactivity disorder.
Spencer T; Biederman J; Wilens T
Psychiatr Clin North Am; 2004 Jun; 27(2):361-72. PubMed ID: 15064002
[TBL] [Abstract][Full Text] [Related]
4. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.
Spencer T; Biederman J; Wilens T; Doyle R; Surman C; Prince J; Mick E; Aleardi M; Herzig K; Faraone S
Biol Psychiatry; 2005 Mar; 57(5):456-63. PubMed ID: 15737659
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
Carpentier PJ; de Jong CA; Dijkstra BA; Verbrugge CA; Krabbe PF
Addiction; 2005 Dec; 100(12):1868-74. PubMed ID: 16367988
[TBL] [Abstract][Full Text] [Related]
6. Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy.
Rao JK; Julius JR; Breen TJ; Blethen SL
Pediatrics; 1998 Aug; 102(2 Pt 3):497-500. PubMed ID: 9685452
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of stimulants in adult ADHD.
Maidment ID
Ann Pharmacother; 2003 Dec; 37(12):1884-90. PubMed ID: 14632541
[TBL] [Abstract][Full Text] [Related]
8. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial.
Akhondzadeh S; Tavakolian R; Davari-Ashtiani R; Arabgol F; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):841-5. PubMed ID: 12921918
[TBL] [Abstract][Full Text] [Related]
9. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
11. [Prescribing ritalin in combined modality management of hyperactivity with attention deficit].
Bricard C; Boidein F
Encephale; 2001; 27(5):435-43. PubMed ID: 11760693
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).
NIH Consens Statement; 1998 Nov 16-18; 16(2):1-37. PubMed ID: 10868163
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
[TBL] [Abstract][Full Text] [Related]
14. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
[TBL] [Abstract][Full Text] [Related]
16. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
17. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Fallu A; Richard C; Prinzo R; Binder C
Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
[TBL] [Abstract][Full Text] [Related]
18. Attention-deficit/hyperactivity disorder: a life-span perspective.
Biederman J
J Clin Psychiatry; 1998; 59 Suppl 7():4-16. PubMed ID: 9680048
[TBL] [Abstract][Full Text] [Related]
19. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder.
Higgins ES
J Fam Pract; 1999 Jan; 48(1):15-20. PubMed ID: 9934377
[TBL] [Abstract][Full Text] [Related]
20. Open-label use of placebos in the treatment of ADHD: a pilot study.
Sandler AD; Bodfish JW
Child Care Health Dev; 2008 Jan; 34(1):104-10. PubMed ID: 18171451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
